Melanoma—BRAF-Mutated Disease, Checkpoint Inhibitors, Emerging Trends, and Challenging Cases

2.25 CME
135 MINS
$0 FEE
SAVE
Melanoma—BRAF-Mutated Disease, Checkpoint Inhibitors, Emerging Trends, and Challenging Cases

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by educational grants from Bristol-Myers Squibb, Iovance Biotherapeutics, and Novartis Pharmaceuticals Corporation.


Activity Description

Advances in BRAF-targeted agents and their integration into treatment algorithms for patients diagnosed with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. However, for patients diagnosed with unresectable disease, challenges exist for identifying those who will benefit from first-line targeted therapy versus immune-based therapies. Additionally, the number of advanced melanoma cases has increased by over 50% during the previous decade. This disease can progress quickly, with spread to the regional lymph nodes or distant organs being associated with a poor prognosis. Over the past decade, the US Food and Drug Administration's approval of several targeted agents and immune checkpoint inhibitors (ICI) has significantly shifted treatment paradigms for advanced melanoma. The National Comprehensive Cancer Network (NCCN) Guidelines now recommend ICI-based therapy as a preferred frontline option for newly diagnosed unresectable or metastatic disease. Lastly, targeted and immune-based therapies have advanced clinical outcomes for patients with melanoma. As further therapies are evaluated and approved, challenges in selecting patients who may receive optimal benefit from evolving and current therapies, sequencing of therapies, management of adverse events, and utilizing therapies as mono- or combination-therapy have arisen. Furthermore, the treatment of patients with brain or liver metastases or with uveal melanoma provide challenges regarding the treatment and management algorithm selection.

In this educational activity, experts in the field review the patient, disease, and/or treatment characteristics that may help in clinical decision-making for patients with newly diagnosed BRAF-mutated melanoma. They also evaluate the latest clinical evidence pertaining to the use of targeted and/or checkpoint inhibitors in patients with unresectable BRAF-mutated disease. Faculty also assess the latest long-term and real-world evidence regarding ICI therapy for patients with newly diagnosed advanced melanoma. In addition, experts discuss clinical cases to provide guidance on identifying optimal candidates for frontline therapy, decisions regarding monotherapy versus combination therapy, as well as appropriate treatment duration and management of immune-related adverse events. And finally, experts in the field examine emerging combinations and cellular therapies for the treatment of patients with melanoma and assess the latest evidence regarding the management of patients with melanoma in challenging clinical scenarios.


Target Audience

The intended audience for this activity is oncologists and other professionals interested in the latest clinical advances regarding the management of patients with melanoma.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the latest evidence regarding the use of targeted agents and/or checkpoint inhibitors for use in patients with BRAF-mutated unresectable melanoma.
  • Review the patient, disease, and/or treatment characteristics that may aid in first-line clinical decision-making for patients with BRAF-mutated melanoma.
  • Assess the latest long-term and real-world evidence regarding the use of checkpoint inhibitors for patients with newly-diagnosed advanced melanoma.
  • Evaluate patient and disease characteristics that may help identify patients with melanoma who may benefit from first-line checkpoint inhibitor-based treatment.
  • Review the latest evidence regarding checkpoint inhibitor-based combination approaches for advanced melanoma.
  • Assess the latest evidence regarding the management of patients with melanoma in challenging clinical scenarios.
  • Examine emerging trends in the treatment of patients with melanoma, including novel combinations and cellular therapies.

Activity Chairs

Sanjiv S. Agarwala, MD
Professor of Medicine
Temple University
Philadelphia, PA

Georgina V. Long BSc, PhD, MBBS, FRACP
Professor of Melanoma Medical Oncology and Translational Research
Co-Medical Director Melanoma Institute Australia
The University of Sydney
North Sydney, NSW, Australia

Alexander Shoushtari, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY


Faculty

Omid Hamid, MD
Chief of Research and Immuno-Oncology
The Angeles Clinic & Research Institute
Los Angeles, CA

Steven J. O'Day, MD
Director
Los Angeles Skin Cancer Institute
Director, Clinical Research
Beverly Hills Cancer Center
Beverly Hills, CA

Allison Betof Warner, MD, PhD
Assistant Attending Physician, Melanoma Service Memorial Sloan Kettering Cancer Center
New York, NY


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 17, 2020, through March 16, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 6 of the 9 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chairs and Faculty report the following relationship(s)

Sanjiv S. Agarwala, MD
Consulting Fee: Bristol-Myers Squibb, Merck

Omid Hamid, MD
Consulting Fee: Aduro, Akeso, Amgen, Array, BeiGene, Bristol-Myers Squibb, GlaxoSmithKline, Immunocore, Incyte, Janssen, Merck, NextCure, Novartis, Roche/Genentech, Sanofi Regeneron, Seattle Genetics, Tempus, Zelluna
Speakers Bureau: Array, Bristol-Myers Squibb, Novartis, Sanofi Regeneron
Contracted Research: Arcus, Aduro, Akeso, Amgen, Array, Bristol-Myers Squibb, CytomX, Exelixis, GlaxoSmithKline, Immunocore, Incyte, Iovance, Merck/Moderna, Merck/Serono, NextCure, Novartis, Roche/Genentech, Sanofi Regeneron, Seattle Genetics, Torque Therapeutics, Zelluna

Georgina V. Long BSc, PhD, MBBS, FRACP
Consulting Fee: Amgen, Bristol-Myers Squibb, MSD/Merck, Novartis, Pierre Fabre
Contracted Research: Amgen, Bristol-Myers Squibb, MassARRAY, MSD/Merck, Novartis, Pierre Fabre, Roche
Honoraria: Bristol-Myers Squibb, MSD/Merck, Novartis, Pierre Fabre

Steven J. O'Day, MD
Consulting Fee: Array, BioNTech, Biothera, Bristol-Myers Squibb, Exicure, ImmunoSYS, Merck, Radimmune, Ultimovacs
Speakers Bureau: Bristol-Myers Squibb
Contracted Research: Agenus, Amgen, Biothera, Bristol-Myers Squibb, Genocea, Incyte, Merck, Ultimovacs, Viralytics

Alexander Shoushtari, MD
Consulting Fee: Bristol-Myers Squibb, Immunocore
Contracted Research: Bristol-Myers Squibb, Immunocore, Xcovery

Allison Betof Warner, MD, PhD
Non-CME Services Fees: LG Chem Life Sciences
Contracted Research: Leap Therapeutics

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com